Phase II Pilot Study Evaluating Strategies to Overcome Resistance at the Time of Progression for Patients With Non-small Cell Lung Cancers Harboring Major Oncogenic Drivers
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Mar 2017 Status changed from not yet recruiting to recruiting.
- 26 Jan 2017 Planned primary completion date changed from 1 Dec 2020 to 1 Feb 2021.
- 26 Jan 2017 Planned initiation date changed from 1 Dec 2016 to 1 Feb 2017.